Trump administration revamps addiction treatment playbook
Add Axios as your preferred source to
see more of our stories on Google.
Illustration: Shoshana Gordon/Axios
The Trump administration is overhauling federal addiction policy and moving away from harm reduction strategies through steps like cutting federal funding for fentanyl test strips.
Why it matters: Many Republicans have long argued these strategies can promote addiction, but clinicians and treatment advocates worry the shifts underway could deter people from getting care.
State of play: The Substance Abuse and Mental Health Services Administration last month cut off federal funding for test strips used to check if street drugs are laced with fentanyl, except if they're used by law enforcement or health care professionals.
- It also halted funding for programs that distribute sterile syringes to people who inject drugs. The syringes have become a key part of the opioid response and are credited with slowing infectious disease spread.
- "It is essential that the use of federal funding is aligned to common-sense public health strategies that focus on prevention, treatment, and long-term recovery," Christopher Carroll, SAMHSA's principal deputy assistant secretary, wrote to program operators.
- The administration continues to make funding available for overdose reversal medication like naloxone.
Between the lines: The moves build on previous administration efforts to encourage more counseling and other prevention-focused approaches.
- But the pivot appears at odds with the White House's own National Drug Control Strategy, which endorses efforts to keep watch on the drug supply to understand emerging threats.
- "Rapid test strips and similar technologies that detect fentanyl and other drugs are an important tool that should be legal and not considered drug paraphernalia," the strategy states.
- A Department of Health and Human Services spokesperson, asked about the apparent contradiction, said the SAMHSA guidance doesn't apply to certain groups who use them in their professional duties.
- The administration in its 2027 budget request also proposed about $10 billion in cuts that would affect community-based treatment and overdose response.
Evidence suggests harm reduction efforts generally decrease overdose deaths and make it likelier people will seek out addiction treatment services.
Zoom out: Some clinicians say the administration's mixed messaging also extends to medication-assisted treatment for opioids, like methadone.
- SAMHSA last month reaffirmed support for medication treatment but directed clinicians to talk to patients at least once a year about whether they should stay on it, and said lifelong medication should "not [be] the default for all patients."
Where it stands: Both SAMHSA's guidance and the White House strategy document emphasize the need for behavioral therapy, support groups and other interventions for people facing addiction.
- The drug control strategy also emphasizes "the healing power of faith," and calls on the country to "bolster the social norm that most people do not use drugs," SAMHSA's Carroll wrote.
The intrigue: President Trump's recent order promoting psychedelic drugs as potential mental health therapies while pulling back on harm reduction seems like a double standard, some addiction treatment advocates say.
- "They are separating classes of drug users," said Lauren Kestner, director of harm reduction at the Center for Prevention Services in North Carolina.
- "That's where a lot of the gaslighting, for me, comes in."
- HHS said the administration is accelerating psychedelics research and approvals because the drugs could save lives and help address the mental illness and addiction crises.
What we're watching: The administration's approach could influence whether overdose deaths continue to fall, and by how much.
